Easy Global Training’s Post

The #animalmodel market size is expected to grow significantly, owing to a surge in the usage of animal models in virology and infectious diseases, the physiological similarity of humans and animals for #drugtesting, an increase in the adoption of #CRISPR (clustered regularly interspaced short palindromic repeats) technology. Want To Know More: https://lnkd.in/dy-izhXh #AMR #AnimalModelMarket #VirologyResearch #InfectiousDiseases #DrugTesting #CRISPRTechnology #BiomedicalResearch #PreclinicalStudies #Pharmaceuticals #HealthcareInnovation #MedicalAdvancements

Thoughts on this? >> CBER's Marks points to stockpiles of H5N1 vaccine as officials monitor reported human case >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #pharma #biotech

🐰 💉 We participated as a Silver Sponsor at the ICARE Congress, held from May 20th to 24th in Ghent, Belgium. The event brought together over 700 attendees from 45 different countries, specializing in exotic and companion animals. We presented three scientific posters and conducted two oral communications related to our new vaccine against Rabbit Haemorrhagic Disease (RHD) that generated a lot of interest among attendees, with the participation of over 400 people. During the presentations, all efficacy study results used for the registration of our new vaccine with the European Medicines Agency (EMA) were shown, highlighting the very good protective results against highly virulent strains of RHDV2. These results make our vaccine the only recombinant vaccine indicated for protection against highly virulent strains of RHDV2. #AnimalHealth #RHD #RabbitProtection

The comprehensive range of animal models from Envigo ++++ for infectious diseases are crucial for understanding disease mechanisms, evaluating therapeutic responses, and developing effective vaccines. Explore the models below to find the ideal fit for your research needs. Whether you're studying viral entry mechanisms, immune responses, or the progression of diseases related to infectious agents, these models provide the precision and reliability essential for drug discovery and development. For enquiries on infectious disease models, fill this form: https://gvrp.in/enquiry/ GV Safety Assessment Platform (GVSAP), a subsidiary of GV Research Platform (GVRP), is a Hyderabad-based pre-clinical CRO and an authorized breeder and distributor of Envigo ++++’s (an Inotiv company) research models & services in India. For more information: 📨 Email: info@gvrp.in 🌐 Website: www.gvrp.in #InfectiousDiseases #ResearchModels #DrugDiscovery #AnimalModels #CRO #LifeSciences #InVivoStudies #BiomedicalResearch #GVRP #drugdevelopment #micemodels #humanizedmice

💊 𝗩𝗼𝗿𝗶𝗰𝗼𝗻𝗮𝘇𝗼𝗹𝗲 is considered the 𝗱𝗿𝘂𝗴 𝗼𝗳 𝗰𝗵𝗼𝗶𝗰 for the treatment of 𝗶𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗮𝘀𝗽𝗲𝗿𝗴𝗶𝗹𝗹𝗼𝘀𝗶𝘀 due to its superior 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗔𝘀𝗽𝗲𝗿𝗴𝗶𝗹𝗹𝘂𝘀 species and better clinical outcomes in treating this serious fungal infection. #MedEd #Medek #Medexx #antifungals #pharmacology #clinicalpearls

Rift Valley Fever Virus (RVFV) is classified as a Category A Priority Pathogen (NIAID), a select agent (HHS and USDA) and a priority (WHO) and notifiable disease (OIE) by several organizations due to its public and animal health impacts. Currently, we have a few licensed vaccines for veterinary use but no licensed vaccines or antivirals for human use. Besides working on a vaccine candidate, with the below study we identified three small molecule compounds inhibiting RVFV in vitro. Candidate compounds were selected through high throughput screening of millions of commercially available small molecules using a structure-based artificial intelligence bioactivity predictor. https://lnkd.in/eisvnfN7

Researchers Use Artificial Intelligence to Identify New Antibiotic  Researchers used artificial intelligence to identify the antibiotic halicin, which can control many antibiotic-resistant strains. #equinevet #horsehealth #veterinarymedicine #veterinaryresearch

📢 Exciting Update! EMA’s Annual Report 2023 is Now Live! 📢 We are thrilled to announce the release of the EMA Annual Report 2023, which details our significant contributions to public and animal health across the European Union. This year's report comes with a fresh layout and new interactive features, offering a deep dive into our strategic initiatives and priority areas. 🌟 Key Highlights: Human Medicines: Recommended the authorization of 77 medicines, including 39 new active substances. Noteworthy approvals include two RSV vaccines and the first CRISPR/Cas9 gene-editing therapy for beta thalassemia and severe sickle cell disease. Veterinary Medicines: Recommended 14 medicines, with nine new active substances and nine vaccines, highlighting a significant leap in veterinary health. Strategic Initiatives: Launch of the ‘Cancer Medicines Pathfinder’ to accelerate cancer drug development and approval. Data-Driven Regulation: Significant progress in leveraging data to drive innovation and regulation. Transparency and Communication: Enhanced efforts to provide clear, timely information through various channels. The digital report is designed for easy navigation on all devices, allowing users to filter and interact with the data. Discover how EMA is shaping the future of medicines regulation and making impactful strides in healthcare. Dive into the report today and explore the progress and innovations of 2023! 📊🔍 🔗 https://lnkd.in/dyyYsS9h #EMA #AnnualReport2023 #PublicHealth #VeterinaryHealth #Innovation #MedicinesRegulation #Transparency #CancerMedicines #DataDriven #CRISPR #HealthcareInnovation

📢 Exciting Update! EMA’s Annual Report 2023 is Now Live! 📢 We are thrilled to announce the release of the EMA Annual Report 2023, which details our significant contributions to public and animal health across the European Union. This year's report comes with a fresh layout and new interactive features, offering a deep dive into our strategic initiatives and priority areas. 🌟 Key Highlights: Human Medicines: Recommended the authorization of 77 medicines, including 39 new active substances. Noteworthy approvals include two RSV vaccines and the first CRISPR/Cas9 gene-editing therapy for beta thalassemia and severe sickle cell disease. Veterinary Medicines: Recommended 14 medicines, with nine new active substances and nine vaccines, highlighting a significant leap in veterinary health. Strategic Initiatives: Launch of the ‘Cancer Medicines Pathfinder’ to accelerate cancer drug development and approval. Data-Driven Regulation: Significant progress in leveraging data to drive innovation and regulation. Transparency and Communication: Enhanced efforts to provide clear, timely information through various channels. The digital report is designed for easy navigation on all devices, allowing users to filter and interact with the data. Discover how EMA is shaping the future of medicines regulation and making impactful strides in healthcare. Dive into the report today and explore the progress and innovations of 2023! 📊🔍 🔗 https://lnkd.in/dyyYsS9h #EMA #AnnualReport2023 #PublicHealth #VeterinaryHealth #Innovation #MedicinesRegulation #Transparency #CancerMedicines #DataDriven #CRISPR #HealthcareInnovation